Navigation Links
Telecommunications Technology Boosts Revenue Generation by Billions and Builds Positive Brand Experience
Date:10/29/2007

Organon Canada extends the Remind Me Today! reminder program

TORONTO, Oct. 29 /PRNewswire/ - Organon Canada continues to benefit from its Remind Me Today! reminder program for its Linessa(R) and Nuvaring(R) contraceptive brands. Women are delighted by the free telephone-based program that helps them remember their contraceptives and Organon Canada is receiving excellent feedback from their sales reps, physicians and patients.

Organon Canada initiated the Remind Me Today! telephone-based reminder program in February 2007 in an effort to improve brand recognition and offer women a valuable, cost-effective and lifestyle-friendly reminder solution. The number of registrations continues to increase every month, exceeding expectations with a retention rate of higher than 91%.

A closer look at the problem of medication non-compliance reveals that unfilled and unused prescriptions are responsible for over 125,000 deaths in the U.S. every year. (2004 Disease Management Directory and Guidebook; Pharma Futures Inc.)

MEMOTEXT(R) adherence programs are a very cost effective way to improve compliance. Depending on the condition and the patient demographics, telephone-based reminder programs have been shown to increase compliance between 8% and 40%. The MEMOTEXT(R) personalized adherence solution sends automated interactive daily text or voice call reminders to a patient's home, office or cellular phone.

"Medication non-compliance is a serious issue for the healthcare industry," explains Amos Adler, President of Enterprising Vision Inc., provider of MEMOTEXT(R). "Research shows that dropout rates for anti-hypertensive and cholesterol-lowering drugs can be as high as 50%. Billions of dollars are being lost across the board from government to pharmaceutical companies - dollars that are directly attributable to healthcare-related non-compliance."

Organon Canada, makers of the Linessa(R) and NuvaRing(R) contraceptives, understands the important relationship between successful healthcare outcomes and the use of communications technology. "The Remind Me Today! program offers women a highly effective lifestyle tool that takes the stress out of remembering," says Meena Bhogal, Sr. Product Manager. "By offering our patients this unique value-added service we are creating a very positive brand experience that truly differentiates us in the marketplace."

Treating patients as partners in their own healthcare is key. "Patients want to be educated and they want support with approaches that suit their lifestyles. We know that interactive communications technology can bridge this gap." says Adler.

Continuing its commitment to high quality products for women, Organon Canada has renewed its contract with Toronto's MEMOTEXT(R) to provide women with the custom designed Remind Me Today! program until 2009 with free reminder messages until 2010.

About Organon

Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia. It has extensive expertise in neuroscience and a rich and focused R&D program. Research areas also include immunology and specific areas of oncology. Organon products are distributed in over 100 countries worldwide, of which more than 50 have an Organon subsidiary. Organon is the human healthcare business unit of Akzo Nobel.

Safe Harbor Statement

This press release may contain forward-looking statements. These forward-looking statements, addressing without limitation such key issues as growth strategy, future financial results, market positions, and product development, are based on current expectations of future events and circumstances and can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", "forecast", and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business prospects.

Such forward-looking statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these forward-looking statements. Organon BioSciences undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or circumstances, or otherwise.

The forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Organon BioSciences' business, particularly but without limitation including general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.


'/>"/>
SOURCE MEMOTEXT
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Vedic vibration technology- the new cure for arthritis
2. Biotechnology industry expected to grow into a three billion dollar industry by 2002
3. Biotechnology on the lead
4. New Technology In MRI Scan Help Test Brain Cancer Therapy
5. New technology to decipher neural connections dealing with heredity and environment
6. Emergence Of New Gene Scanning Technology In Disease Research
7. CoQ10 bioavailability increased by Nanotechnology
8. Developing a new vaccine using a new technology
9. Scientists Develop New Technology To Find About Human Ancestors’ Teet
10. T-waves to sweep over imaging technology
11. Nanotechnology Revolution To Be Spearheaded By European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: